Kevin Kunzmann

Peter Marinkovich, MD, reflects on the significant growth in advanced therapy development, particularly in rare skin diseases.

The FDA approved the first 2 therapies to treat molluscum contagiosum in the last year. Silver explains how it's provided more than just treatment options.

Joyce Teng, MD, PhD, discusses how therapeutic advances in fields like epidermolysis bullosa should progress treatment discourse in other rare dermatoses.

Marinkovich discusses how the investigative cell-based graft therapy may serve a key role in the emerging DEB treatment paradigm.

Lio shares 3 aspects of pain management that dermatologists can consider to improve the experience of procedures for patients.

Joyce Teng, MD, PhD, reviews a pair of recently approved agents for DEB—as well as a cell therapy awaiting FDA decision this year.

Gene and cell therapies are reaching patients with the severe forms of epidermolysis bullosa. An expert explains their differing benefits and strengths.

The prominent clinical investigator joins to discuss adjuvant and neoadjuvant care research, as well as the application of biomarkers in personalized care.

In recognition of 60 years since the historic contribution to modern understanding of the harmful effects of cigarette smoking, Albert Rizzo, MD, meets with the preventive cardiology expert to discuss the myriad of cascading effects delivered by the 1964 report.

The first Lungcast of 2024 touches on one of the most pressing issues in medicine: burnout, with an organizational expert.

A systematic review combined with a pair of case studies suggest men who discontinue the front-line treatment for conditions like polycythaemia vera may improve their fertility.

A new analysis suggests up to 3 in 10 patients who have an abnormal CT scan experience complications in follow-up procedures.

Analysis shows that biosimilar uptake was up to 2-fold greater in Medicare Advantage coverage than traditional Medicare.

A systematic review and meta-analysis suggests the dual pathway-targeting faricimab provides some greater benefit in outcomes like CST at fewer injections and without compromise of safety to anti-VEGF monotherapies.

Data from a nationally representative survey show that, despite most US adults agree the COVID-19 and flu vaccines are safe and effective, there is discrepancy in why some may not want one or the other.

Clinicians and investigators alike navigate waning protection against the complex disease to push precedent-setting research and identify new care options.

Califf joins HCPLive to share perspective on AI, gene and cell therapy development, COVID-19, food and substance regulation, maternal and infant health, weight loss intervention, and more.

From breakthroughs in disease intervention and vaccines, to global developments in air quality and COVID-19, Lungcast reflects on the people and stories that shaped this year in pulmonology.

Multinational data support the safety of drug classes like GLP-1 agonists during early relative to infant risk of major congenital malformations.

Phase 3 data show patients with obesity who maintained tirzepatide from weeks 36 to 88 continued significant weight loss versus patients switched to placebo.

Extension analysis from a phase 1 trial show the investigative oral mitapivat was not associated with any discontinuations nor deaths over 2 years.

New case-control data from ASH 2023 show a particularly increased link between sickle cell trait and monocytic and myeloid leukemia progression.

A single-center cohort analysis showed the biosimilar provided similar PBSC mobilization to originator filgrastim.

Lungcast is joined by an environmental engineer to discuss the burden of harmful air in US school systems today.

The approval is the first for a systemic therapy to treat desmoid tumors, offering patients an alternative to surgery.

Safer discusses how symptoms and quality of life often go unaddressed in the few clinician-patient interactions about primary sclerosing cholangitis.

Lassailly discusses the role of bariatric surgery versus weight-loss treatments like semaglutide for patients with MASH.

A cohort analysis shows foreign-born patients are significantly less likely to be immunized for HBV than US-born patients.

An analysis of the AI tool showed it could help translate complex ophthalmology research for various patient levels of comprehension.

Investigators reported that AI programs such as LightGBM could potentially significantly benefit the diagnosis of Berger disease.